Research area
Redoxis holds a portfolio of research projects for the treatment of chronic inflammatory and autoimmune diseases, linked together by a large unmet medical need and large patient populations or high-value niche therapy areas. Redoxis research actively targets pathways identified by forward genetics with the aim of identifying and developing novel small molecule therapies.
Redoxis targets major inflammatory diseases such as Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and Inflammatory Bowel Disease (IBD). In some instances, we target specialized niche indications, for example, peripheral nerve inflammatory conditions like Guillian-Barré syndrome (GBS), Chronic Granulomatous Disease (CGD) and inflammatory uveitis.
Redoxis closely collaborates with academic partners in Sweden, Europe and the U.S. to acquire or license novel projects within Redoxis’ research expertise.
